ArticleScientific data2026
A Unified Dataset for Antibody and Nanobody Design Including Sequence, Structure, and Binding Affinity Data.
Article in Scientific data, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- AVIDbase: A biologically accurate structural dataset of nanobody-antigen complexes.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The design and optimization of antibodies and nanobodies using deep generative models hold transformative potential for therapeutic and diagnostic applications, which are hindered by the fragmented and inconsistent nature of existing datasets. To address these limitations, we introduce the Antibody and Nanobody Design Dataset (ANDD), a unified dataset that integrates sequence, structure, antigen, and affinity data from 15 diverse sources. ANDD is a comprehensive resource comprising 48,683 antibody/nanobody sequences, with structural data for 24,941 entries, and antigen sequences for 12,575 entries. We further augmented the affinity data with 2,271 predicted affinity values using ANTIPASTI, a robust model for binding affinity prediction. Consequently, ANDD includes 9,557 affinity values, making it the largest dataset to date for antibody/nanobody and antigen pairs with affinity data. By addressing challenges of data fragmentation and inconsistency, ANDD provides a robust foundation for training deep generative models. With ANDD, the models can better model antibody/nanobody-antigen interactions, while design novel antibodies and nanobodies with improved specificity and efficacy, paving the way for development of targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.